Natalizumab Therapy for Multiple Sclerosis

Neurotherapeutics

Volumn 10, Issue 1, 2013, Pages 19-28

  Chataway, Jeremy ^a   Miller, David H ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Natalizumab; Progressive multifocal leucoencephalopathy; Relapsing remitting MS

Indexed keywords

BETA INTERFERON 1A; CORTICOSTEROID; FIRATEGRAST; MARAVIROC; MEFLOQUINE; MIRTAZAPINE; NATALIZUMAB; RECOMBINANT BETA INTERFERON; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ALLERGIC ENCEPHALITIS; ALLERGIC REACTION; BLOOD BRAIN BARRIER; CELL ADHESION; CELL MIGRATION; CLINICAL PRACTICE; CONTRAST ENHANCEMENT; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; HISTOPATHOLOGY; HUMAN; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; LIVER FUNCTION; LYMPHOCYTIC INFILTRATION; MULTIPLE SCLEROSIS; NAUSEA; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHARYNGITIS; PLASMAPHERESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; QUALITY ADJUSTED LIFE YEAR; REVIEW; TREATMENT DURATION; VIRUS REPLICATION;

EID: 84873185064     PISSN: 19337213     EISSN: 18787479     Source Type: Journal    
DOI: 10.1007/s13311-012-0171-4     Document Type: Review

References (54)

1. Elices MJ, Osborn L, Takada Y, et al. VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site. Cell 1990; 60: 577-584.
2. Yednock TA, Cannon C, Fritz LC, et al. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 1992; 356: 63-66.
3. Miller DH, Rudge P, Johnson G, et al. Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis. Brain. 1988; 111: 927-939.
4. Youl BD, Turano G, Miller DH, et al. The pathophysiology of acute optic neuritis: an association of gadolinium leakage with clinical and electrophysiological deficits. Brain 1991; 114: 2437-2450.
5. Hawkins CP, Munro PM, MacKenzie F, et al. Duration and selectivity of blood-brain barrier breakdown in chronic relapsing experimental allergic encephalomyelitis studied by gadolinium-DTPA and protein markers. Brain 1990; 113: 365-378.
6. Katz D, Taubenberger JK, Cannella B, McFarlin DE, Raine CS, McFarland HF. Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis. Ann Neurol 1993; 34: 661-669.
7. Tubridy N, Behan PO, Capildeo R, et al. The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group. Neurology 1999; 53: 466-472.
8. O'Connor PW, Goodman A, Willmer-Hulme AJ, et al. Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects. Neurology 2004; 62: 2038-2043.
9. Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003; 348: 15-23.
10. Dalton CM, Miszkiel KA, Barker GJ, et al. Effect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis. J Neurol 2004; 251: 407-413.
11. Giuliani P, Solari A, Simi S, et al. Natalizumab for relapsing remitting multiple sclerosis. Cochrane Database Syst Rev 2011, Issue 10. Art. No. CD007621.
12. Polman CH, O'Connor PW, Havrdová E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899-910.
13. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006; 354: 911-923.
14. Goodman AD, Rossman H, Bar-Or A, et al. GLANCE: Results of a phase 2, randomized, double-blind, placebo-controlled study. Neurology 2009; 72: 806-812.
15. Horga A, Tintore M. Natalizumab for relapsing-remitting multiple sclerosis. Neurologia 2011: 26: 357-368.
16. Havadrova E, Galetta S, Hutchinson M, et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the natalizumab safety and efficacy in relapsing-remitting multiple sclerosis (AFFIRM) study. Lancet Neurol 2009; 8: 254-260.
17. National Institute for Health and Clinical Excellence. Natalizumab for the treatment of adults with highly active relapsing-remitting multiple sclerosis, 2007. Available at: www. nice. org. uk/TA127. Accessed 7 Sept 2012.
18. Balcer LJ, Galetta SL, Calabresi PA, et al. Natalizumab reduces visual loss in patients with relapsing multiple sclerosis. Neurology 2007; 68: 1299-1304.
19. Rudick RA, Miller D, Hass S, et al. Health-related quality of life in multiple sclerosis: effects of natalizumab. Ann Neurol 2007; 62: 355-346.
20. Miller DH, Soon D, Fernando KT, et al. MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology 2007; 68: 1390-1401.
21. Soon D. A study of grey and white matter atrophy in a placebo-controlled trial of natalizumab in relapsing remitting multiple sclerosis. In: Soon D MRI evaluation of the anti-adhesion molecule antibody Natalizumab and the blood-brain barrier in Multiple Sclerosis PhD Thesis. UCL. 2010; Pg 117-149.
22. Soon D, Altmann DR, Fernando KT, et al. A study of subtle blood brain barrier disruption in a placebo-controlled trial of natalizumab in relapsing remitting multiple sclerosis. J Neurol 2007; 254: 306-314.
23. Radue EW, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis. J Neurol Sci 2010; 292: 28-35.
24. Philips J, O'Connor P, Havrdova E, et al. Infusion-related hypersensitivity reactions during natalizumab treatment. Neurology 2006; 67: 1717-1718.
25. Ransohoff R. Natalizumab for multiple sclerosis. NEJM 2007; 356: 2622-2629.
26. Kwiatkowski A, Gallois J, Bilbault N, et al. Herpes encephalitis during natalizumab treatment in multiple sclerosis. Multiple Sclerosis 2012; 18: 909-911.
27. Seiguer Shenoy E, Mylonakis E, Hurtado RM, et al. Natalizumab and HSV meningitis. J Neurovirol 2011; 17: 288-290.
28. Scheiss N, Zong J, Hayward G, et al. Reactivation of herpes virus in multiple sclerosis patients on natalizumab therapy. Poster Presentation at the American Academy of Neurology 61st Annual Meeting, Seattle, WA, April 28 2009, P03. 163.
29. Zecca C, Nessi F, Bernasconi E, et al. Ocular toxoplasmosis during natalizumab treatment. Neurology. 2009; 73: 1418-1419.
30. Gutwinski S, Eerbe S, Munch C, et al. Severe cutaneous Candida infection during natalizumab therapy in multiple sclerosis. Neurology 2010; 74: 521-523.
31. Schweikert A, Kremer M, Ringel F, et al. Primary central nervous system lymphoma in a patient treated with natalizumab. Ann Neurol 2009; 66: 403-406.
32. Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005; 353: 369-374.
33. Langer-Gould A, Atlas SW, Green AJ, et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005; 353: 375-381.
34. van Assche G., van RM, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005; 353: 362-368.
35. Yousry TA, Major EO, Ryschkewitsch C, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 2006; 354: 924-933.
36. Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 2012; 366: 1870-1880.
37. Cinque P, Koralnik IJ, Gerevini S, et al. Progressive multifocal leukoencephalopathy in HIV-1 infection. Lancet Infect Dis 2009; 9: 625-636.
38. Kean JM, Rao S, Wang M, et al. Seroepidemiology of human polyomaviruses. PLoS Pathog 2009; 5: e1000363.
39. Sunyaev S, Lugovskoy A, Simon A, et al. Adaptive mutations in the JC virus protein capsid are associated with progressive multifocal leukoencephalopathy (PML). PLoS Genet 2009; 5: e1000368.
40. Berger J. The clinical features of PML. Cleveland Clin J Med 2011; 78(Suppl. 2): S8-S12.
41. Dong-Si T, Richman S, Gangadharan A, et al. Functional disability after natalizumab-associated PML in a large cohort of survivors. MS Journal 2012; 18(suppl 4): 516.
42. Stefoski D, Ko M, Javed A, et al. Novel interventions with favorable resolution of natalizumab-induced progressive multifocal leukoencephalopathy (PML). Neurology April 22, 2012 78: P07. 062.
43. Khatri B, Man S, Giovannoni G, et al. Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology 2009; 72: 402-409.
44. Tan I, McArthur J, Clifford D, et al. Immune reconstitution inflammation syndrome in natalizumab-associated PML. Neurology 2011; 77: 1061-1067.
45. Clifford DB, De LA, Simpson DM, et al. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 2010; 9: 438-446.
46. Gorelik L, Lerner M, Bixler S, et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol 2010; 68: 295-303.
47. Bozic C, Richman S, Plavina T, et al. Anti-JCV antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1. Ann Neurol 2011; 70: 742-750.
48. Hunt D, Giovannoni G. Natalizumab-associated progressive multifocal leucoencephalopathy: a practical approach to risk profiling and monitoring. Pract Neurol 2012; 12: 25-35.
49. Ayzenberg I, Lukas C, Trampe N, et al. Value of MRI as a surrogate marker for PML in natalizumab long-term therapy. J Neurol 2012; 259: 1732-1733.
50. Yousry T, Pelletier D, Cadavid D, et al. Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 2012 (in press).
51. Richert N, G. Bloomgren, D. Cadavid, et al. Imaging findings for PML in natalizumab-treated MS patients. MS Journal 2012; 18(Suppl. 4): 27-28.
52. O'Connor PW, Goodman A, Kappos L, et al. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology 2011; 76: 1858-1865.
53. Zecca C, Meier S, Tschuor S, et al. Natalizumab de-escalation to interferon-b-1b in multiple sclerosis: a randomised, controlled, pilot trial. MS Journal 2012; 18(Suppl. 4): 463.
54. Miller DH, Weber T, Groves R, et al. Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2012; 11: 131-139.